Explore: Biotech · Series A · Series B · Series C
Jeito Capital
Investment Thesis
Jeito’s investment thesis is centered on financing and accelerating breakthrough biopharma innovation from clinical development through market access, with an emphasis on companies that can become leaders in therapeutic areas with substantial unmet medical need. The firm appears to favor clinical-stage opportunities primarily in Europe, while also supporting growth of portfolio companies in the United States, and it allocates large amounts of capital per company to help advance assets through the expensive late-stage drug development path.
About Jeito Capital
Jeito Capital is a Paris-based, fully independent life sciences investor focused on biopharma and innovative medical companies. It backs clinical-stage companies developing breakthrough therapies for severe diseases with high unmet medical need, and it typically provides significant follow-on capital plus operational support through development and commercialization.
Sectors
Stages
Geographic focus
Notable Investments
null
Verified 9 April 2026 · Sources: company website, Fusion42 review
Frequently asked questions
- What does Jeito Capital invest in?
- Jeito Capital invests in Biotech at the series-a, series-b and series-c stages.
- Which geographies does Jeito Capital focus on?
- Jeito Capital focuses on Europe, Global and United States, and is headquartered in France.
- What is Jeito Capital's typical check size?
- Jeito Capital typically writes checks of up to $150M.